Vor Biopharma Inc (VOR)

• $0.68

  $0.73

  $0.68
  

  0.72%

  Downside

  Day's Volatility :7.52%

  Upside

  6.85%

  
• $0.63

  $3.14

  $0.68
  

  7.35%

  Downside

  52 Weeks Volatility :79.94%

  Upside

  78.34%

  

Returns

What analysts predicted

Upside of 1839.71%

• RA Capital Management, LLC

  33.26%

• FMR Inc

  10.34%

• Paradigm Biocapital Advisors LP

  9.44%

• 5AM Venture Management, LLC

  9.30%

• LAURION CAPITAL MANAGEMENT LP

  3.69%

• Vanguard Group Inc

  2.86%

vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar